Saturday 17 October 2026
Export PBYI’s income statement to Excel — free account
Puma Biotechnology, Inc.
PBYI Healthcare Biotechnology
Puma Biotechnology, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $228.4 million, down 0.91% from fiscal 2024. In the quarter to June 2026, revenue grew 7.75%, EPS grew 33.3%, free cash flow fell 88.5% and total debt fell 79.8%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.
9.83
0.69
−6.56%
Follow PBYI
| Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
— | — | — | 5 | 4 | 4 | 4 | 6 | 5 | 8 |
P/E ratio |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1,966.67 | 9.85 | 5.00 | 9.44 |
P/S ratio |
— | 0.00 | 3.08 | 1.25 | 1.80 | 0.49 | 0.81 | 0.91 | 0.64 | 1.30 |
Altman Z-Score |
— | 5.12 | (4.04) | (5.68) | (6.03) | (6.82) | (6.36) | (5.69) | (6.05) | (4.16) |
P/FCF ratio |
— | 0.00 | 0.00 | 15.78 | 0.00 | 12.00 | 0.00 | 14.88 | 5.64 | 10.18 |
Altman Z″-Score (non-manufacturers) |
— | (30.90) | (13.98) | (16.66) | (17.86) | (18.76) | (17.56) | (16.14) | (16.73) | (14.13) |
Beneish M-Score |
— | — | 2.20 | (3.91) | (3.57) | (3.27) | (1.81) | (2.45) | (2.90) | (2.06) |
P/Operating CF |
— | (96.71) | 109.57 | 216.62 | (72.06) | (22.73) | 24.02 | 20.42 | 9.51 | 20.64 |
P/B ratio |
— | 64.61 | 22.51 | 19.43 | 0.00 | 0.00 | 8.54 | 4.00 | 1.61 | 2.28 |
Price to Tangible BV |
— | 696.13 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.62 | 3.35 |
EV/Sales |
— | 0.00 | 3.02 | 1.16 | 1.79 | 0.53 | 0.90 | 0.92 | 0.50 | 1.01 |
EV/EBITDA |
— | 0.00 | 0.00 | 0.00 | 0.00 | 10.58 | 6.13 | 4.92 | 2.69 | 4.80 |
EV/Operating CF |
— | (19.77) | (31.47) | 14.14 | 520.21 | 6.45 | (13.01) | 8.04 | 2.94 | 5.53 |
EV/FCF |
— | (19.73) | (30.69) | 14.71 | (41.98) | 12.94 | (8.88) | 15.14 | 4.35 | 7.91 |
Quick Ratio |
6.13 | 1.57 | 2.77 | 1.64 | 1.12 | 1.13 | 1.57 | 1.45 | 1.38 | 1.89 |
Current Ratio |
6.31 | 1.82 | 3.02 | 1.83 | 1.28 | 1.28 | 1.73 | 1.57 | 1.54 | 2.00 |
Net Debt/EBITDA |
0.83 | 0.11 | 0.16 | 0.74 | 0.19 | 0.77 | 0.64 | 0.08 | (0.80) | (1.60) |
Debt/Assets |
0.00% | 29.29% | 58.62% | 41.54% | 40.26% | 44.43% | 46.14% | 43.23% | 31.43% | 10.41% |
Debt/Equity |
0.00 | 0.91 | 4.43 | 5.59 | (16.52) | (41.16) | 4.74 | 1.86 | 0.73 | 0.17 |
Asset Turnover |
0.00 | 0.13 | 1.18 | 1.10 | 0.94 | 1.08 | 1.02 | 1.04 | 1.04 | 1.06 |
Operating CF/Net income |
0.51 | 0.59 | 0.21 | (0.30) | (0.01) | (0.71) | (7,913.50) | 1.25 | 1.29 | 1.34 |
Capex/Depreciation |
(6.34) | (17.94) | (0.08) | (0.04) | (1.00) | 0.00 | (0.71) | (1.10) | 0.00 | (0.01) |
Interest Coverage |
(288.72) | (406.10) | (8.62) | (2.60) | (2.16) | 0.10 | 2.05 | 2.45 | 2.49 | 5.63 |
| (132.75%) | (221.91%) | (259.28%) | (292.05%) | (1,042.29%) | 693.73% | 0.02% | 57.54% | 41.60% | 27.97% | |
| (112.06%) | (139.59%) | (53.49%) | (30.60%) | (25.04%) | (12.37%) | 0.00% | 9.54% | 13.64% | 14.48% | |
ROIC |
0.00% | (910.03%) | (284.82%) | 0.00% | 0.00% | 11.10% | 34.49% | 35.69% | 33.25% | 43.78% |
Return on Tangible Assets |
(135.19%) | (555.85%) | (81.21%) | (95.98%) | (174.58%) | (90.48%) | 0.00% | 37.45% | 58.16% | 38.12% |
Average Days of Receivables |
— | 127.49 | 30.21 | 38.74 | 41.42 | 46.90 | 64.59 | 74.10 | 50.70 | 85.75 |
Research and Development Expense of Revenue |
0.00% | 750.62% | 65.68% | 48.80% | 43.38% | 28.39% | 22.91% | 21.38% | 23.84% | 27.18% |
Selling, General and Administrative Expense of Revenue |
0.00% | 385.38% | 58.24% | 52.02% | 52.64% | 45.94% | 39.46% | 38.17% | 34.78% | 31.02% |
Intangible Assets out of Total Assets |
0.00 | 0.29 | 0.17 | 0.17 | 0.30 | 0.29 | 0.32 | 0.26 | 0.24 | 0.19 |
Share Based Compensation of Revenue |
0.00% | 392.76% | 34.64% | 21.06% | 16.25% | 12.89% | 5.19% | 4.35% | 3.58% | 3.04% |
Graham Net Nets |
— | 0.00 | (0.03) | (0.15) | (0.26) | (0.72) | (0.36) | (0.10) | 0.18 | 0.26 |
Graham Number |
— | 0.00 | 0.00 | 0.00 | 2.26 | 0.98 | 0.15 | 3.43 | 5.10 | 6.08 |
Earnings Yield |
— | (8.47%) | (14.69%) | (22.40%) | (14.72%) | (23.36%) | 0.05% | 10.15% | 20.00% | 10.59% |
Free Cash Flow Yield |
— | (5.02%) | (3.20%) | 6.34% | (2.36%) | 8.34% | (12.56%) | 6.72% | 17.74% | 9.82% |
Revenue per Share |
0.00 | 0.74 | 6.62 | 7.02 | 5.69 | 6.23 | 5.10 | 5.00 | 4.74 | 4.57 |
Operating CF per Share |
(4.26) | (4.64) | (0.64) | 0.58 | 0.02 | 0.51 | (0.35) | 0.57 | 0.80 | 0.84 |
Capex per Share |
(0.22) | (1.36) | (0.02) | (0.01) | (0.25) | 0.00 | (0.16) | (0.27) | 0.00 | 0.00 |
Free Cash Flow per Share |
(4.47) | (6.00) | (0.65) | 0.57 | (0.23) | 0.51 | (0.51) | 0.30 | 0.80 | 0.83 |
Cash per Share |
6.89 | 2.20 | 4.36 | 3.11 | 2.58 | 2.24 | 1.81 | 2.04 | 2.08 | 1.99 |
Shareholders Equity per Share |
6.30 | 1.43 | 0.90 | 0.45 | (0.15) | (0.06) | 0.48 | 1.13 | 1.89 | 2.61 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
6.30 | 1.43 | 0.90 | 0.45 | (0.15) | (0.06) | 0.48 | 1.13 | 1.89 | 2.61 |
Free Cash Flow |
(148.97) | (222.90) | (24.71) | 22.07 | (9.27) | 20.65 | (22.83) | 14.37 | 38.86 | 41.73 |
Working Capital |
199.01 | 48.05 | 135.89 | 75.46 | 31.88 | 30.44 | 56.80 | 56.80 | 51.55 | 81.43 |
Capital Expenditures |
(7.28) | (50.43) | (0.61) | (0.31) | (10.05) | — | (7.00) | (12.64) | (0.06) | (0.07) |
Net Current Asset Value |
193.51 | (5.83) | (21.81) | (51.15) | (104.03) | (89.01) | (66.17) | (20.90) | 26.45 | 76.72 |
EV/EBIT |
— | 0.00 | 0.00 | 0.00 | 0.00 | 103.30 | 8.68 | 6.66 | 3.70 | 6.20 |
Capex to Sales |
0.00 | 1.82 | 0.00 | 0.00 | 0.04 | 0.00 | 0.03 | 0.05 | 0.00 | 0.00 |
Price to Operating Income |
— | 0.00 | 0.00 | 0.00 | 0.00 | 95.77 | 7.78 | 6.54 | 4.79 | 7.98 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.22 | 0.63 | 1.86 | 2.44 | 4.04 | 6.44 | 8.59 | 13.47 | 22.38 | 58.49 |
Cash ROIC |
(33.91%) | (121.49%) | (7.03%) | 9.37% | (4.77%) | 10.92% | (11.13%) | 5.77% | 14.94% | 16.53% |
Accounts Receivable Turnover |
— | 4.84 | 16.49 | 10.96 | 8.27 | 8.72 | 6.26 | 5.34 | 5.77 | 5.33 |
Accounts Payable Turnover |
0.06 | 0.23 | 1.43 | 1.85 | 2.52 | 5.48 | 6.26 | 9.41 | 10.39 | 11.01 |
Inventory Turnover |
0.00 | 2.39 | 14.88 | 12.71 | 11.89 | 12.06 | 9.47 | 10.80 | 8.15 | 8.17 |
Average Days of Payables |
6,364.47 | 1,814.00 | 218.07 | 190.19 | 111.95 | 64.03 | 42.67 | 40.11 | 31.22 | 31.73 |
Days of Inventory on Hand |
0.00 | 132.91 | 27.67 | 31.43 | 32.02 | 40.73 | 29.99 | 41.23 | 49.44 | 34.61 |
Average Receivables |
— | 5.72 | 15.22 | 24.83 | 27.22 | 29.03 | 36.44 | 44.09 | 39.92 | 42.83 |
Average Payables |
18.92 | 23.86 | 24.19 | 19.93 | 15.63 | 11.63 | 8.81 | 6.66 | 6.20 | 5.28 |
Average Inventory |
— | 2.33 | 2.33 | 2.90 | 3.31 | 5.28 | 5.82 | 5.80 | 7.90 | 7.12 |
Average Assets |
246.32 | 209.16 | 212.32 | 247.01 | 239.56 | 235.40 | 224.32 | 226.29 | 221.93 | 214.82 |
Average Common Equity |
207.92 | 131.56 | 43.80 | 25.88 | 5.76 | (4.20) | 9.58 | 37.53 | 72.78 | 111.23 |
Columns are period end dates